导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.37% | 2104/4773 |
| 近一周 | -1.75% | 698/5462 |
| 近一月 | -3.60% | 1854/5421 |
| 近一季 | -6.45% | 2096/5209 |
| 近半年 | -0.32% | 1268/4920 |
| 近一年 | 3.10% | 1997/4366 |
| 近两年 | 44.59% | 1659/2954 |
| 近三年 | 21.95% | 1403/2253 |
| 成立以来 | 73.95% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.59% 2833/4961 |
12.87% 2101/5312 |
- - |
- - |
| 2025 | 18.79% 2280/4813 |
0.64% 1803/3635 |
1.84% 2100/4076 |
14.72% 2877/4524 |
1.03% 1579/4813 |
| 2024 | 11.60% 1310/3463 |
3.72% 519/2808 |
-2.23% 1159/3014 |
13.24% 2210/3129 |
-2.82% 2187/3463 |
| 2023 | -9.51% 1179/2656 |
4.80% 868/2280 |
-4.04% 1022/2385 |
-2.26% 650/2515 |
-7.93% 2224/2655 |
| 2022 | -14.33% 364/2207 |
-11.74% 541/1919 |
6.36% 716/2016 |
-9.74% 304/2113 |
1.12% 1380/2208 |
| 2021 | 9.14% 459/1822 |
3.01% 193/2009 |
7.91% 852/2060 |
-4.57% 1542/2103 |
2.88% 504/1822 |
| 2020 | 32.74% 476/1250 |
-8.18% 1717/1861 |
18.31% 784/1950 |
10.61% 769/2010 |
10.47% 871/2031 |
| 2019 | - - |
- - |
-0.92% 1716/3201 |
5.81% 650/1861 |
7.51% 790/1886 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 财通沪深300指数增强 VS. 长安沪深300非周期A(740101) |